Recently Added Drugs
1. Drug name - ANJESO
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11458145 | BAUDAX | Methods of administering intravenous meloxicam in a bolus dose |
Mar, 2039
(16 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Product (NP) | Feb 20, 2023 |
Drugs and Companies using MELOXICAM ingredient
Market Authorisation Date: 20 February, 2020
Treatment: Management of moderate-to-severe pain by injection
Dosage: SOLUTION;INTRAVENOUS
| Strength | Dosage | Availability |
|---|---|---|
| 30MG/ML (30MG/ML) | SOLUTION;INTRAVENOUS | Prescription |
2. Drug name - ARIKAYCE KIT
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11446318 | INSMED INC | Methods for treating pulmonary non-tuberculous mycobacterial infections |
May, 2035
(12 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity (ODE) | Sep 28, 2025 |
| Generating Antibiotic Incentives Now (GAIN) | Sep 28, 2030 |
Drugs and Companies using AMIKACIN SULFATE ingredient
Market Authorisation Date: 28 September, 2018
Treatment: Treating mycobacterium avium complex (mac) lung disease in adults as part of a combination drug regimen
Dosage: SUSPENSION, LIPOSOMAL;INHALATION
| Strength | Dosage | Availability |
|---|---|---|
| EQ 590MG BASE/8.4ML | SUSPENSION, LIPOSOMAL;INHALATION | Prescription |
3. Drug name - AUSTEDO
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11446291 | TEVA BRANDED PHARM | Methods for the treatment of abnormal involuntary movement disorders |
Mar, 2036
(13 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity (ODE) | Apr 3, 2024 |
| New Chemical Entity Exclusivity (NCE) | Apr 3, 2022 |
| M | Jun 24, 2024 |
| Pediatric Exclusivity (PED) | Oct 3, 2024 |
Drugs and Companies using DEUTETRABENAZINE ingredient
Market Authorisation Date: 03 April, 2017
Treatment: Treatment of tardive dyskinesia
Dosage: TABLET;ORAL
| Strength | Dosage | Availability |
|---|---|---|
| 6MG | TABLET;ORAL | Prescription |
| 9MG | TABLET;ORAL | Prescription |
| 12MG | TABLET;ORAL | Prescription |
4. Drug name - CERDELGA
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US11458119 | GENZYME CORP | Amorphous and a crystalline form of genz 112638 hemitartrate as inhibitor of glucosylceramide synthase |
Nov, 2030
(7 years from now) | |
Drugs and Companies using ELIGLUSTAT TARTRATE ingredient
Market Authorisation Date: 19 August, 2014
Treatment: NA
Dosage: CAPSULE;ORAL
| Strength | Dosage | Availability |
|---|---|---|
| EQ 84MG BASE | CAPSULE;ORAL | Prescription |
5. Drug name - DEXTENZA
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11458041 | OCULAR THERAPEUTIX | Punctal plug and bioadhesives |
Nov, 2037
(14 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Indication (I) | Oct 7, 2024 |
Drugs and Companies using DEXAMETHASONE ingredient
Market Authorisation Date: 30 November, 2018
Treatment: Treatment of ocular itching associated with allergic conjunctivitis; Treatment of ocular inflammation and pain following ophthalmic surgery
Dosage: INSERT;OPHTHALMIC
| Strength | Dosage | Availability |
|---|---|---|
| 0.4MG | INSERT;OPHTHALMIC | Prescription |
6. Drug name - DROSPIRENONE
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11478487 | EXELTIS USA INC |
Jun, 2031
(8 years from now) | ||
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Product (NP) | Jun 29, 2025 |
Drugs and Companies using DROSPIRENONE ingredient
Market Authorisation Date: 29 June, 2022
Treatment: NA
Dosage: TABLET, CHEWABLE;ORAL
| Strength | Dosage | Availability |
|---|---|---|
| 3.5MG | TABLET, CHEWABLE;ORAL | Prescription |
7. Drug name - EMERPHED
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11464752 | NEXUS PHARMS | Compositions comprising ephedrine or an ephedrine salt and methods of making and using same |
May, 2040
(17 years from now) | |
Drugs and Companies using EPHEDRINE SULFATE ingredient
Market Authorisation Date: 17 April, 2020
Treatment: NA
Dosage: SOLUTION;INTRAVENOUS
| Strength | Dosage | Availability |
|---|---|---|
| 50MG/10ML (5MG/ML) | SOLUTION;INTRAVENOUS | Prescription |
8. Drug name - FERRIPROX
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11458103 | CHIESI | Delayed release deferiprone tablets and methods of using the same |
Oct, 2038
(15 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Indication (I) | Apr 30, 2024 |
Drugs and Companies using DEFERIPRONE ingredient
Market Authorisation Date: 19 May, 2020
Treatment: NA
Dosage: TABLET;ORAL
| Strength | Dosage | Availability |
|---|---|---|
| 1GM | TABLET;ORAL | Prescription |
9. Drug name - FUROSCIX
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11433044 | SCPHARMACEUTICALS | Pharmaceutical formulations for subcutaneous administration of furosemide |
Apr, 2034
(11 years from now) | |
| US9884039 | SCPHARMACEUTICALS | Pharmaceutical formulations for subcutaneous administration of furosemide |
Apr, 2034
(11 years from now) | |
| US10272064 | SCPHARMACEUTICALS | Pharmaceutical formulations for subcutaneous administration of furosemide |
Apr, 2034
(11 years from now) | |
Drugs and Companies using FUROSEMIDE ingredient
Market Authorisation Date: 07 October, 2022
Treatment: Use of a liquid formulation comprising furosemide to treat congestion due to fluid overload (edema) in adults with nyha class ii/iii chronic heart failure
Dosage: SOLUTION;SUBCUTANEOUS
| Strength | Dosage | Availability |
|---|---|---|
| 80MG/10ML (8MG/ML) | SOLUTION;SUBCUTANEOUS | Prescription |
10. Drug name - GALAFOLD
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11458128 | AMICUS THERAP US | Methods of treating Fabry patients having renal impairment |
May, 2038
(15 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | Aug 10, 2023 |
| Orphan Drug Exclusivity (ODE) | Aug 10, 2025 |
Drugs and Companies using MIGALASTAT HYDROCHLORIDE ingredient
Market Authorisation Date: 10 August, 2018
Treatment: The treatment of fabry patients
Dosage: CAPSULE;ORAL
| Strength | Dosage | Availability |
|---|---|---|
| EQ 123MG BASE | CAPSULE;ORAL | Prescription |
11. Drug name - IHEEZO
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10792271 | SINTETICA SA | Topical formulations of chloroprocaine and methods of using same |
Sep, 2038
(15 years from now) | |
Drugs and Companies using CHLOROPROCAINE HYDROCHLORIDE ingredient
Market Authorisation Date: 27 September, 2022
Treatment: Method of inducing ocular anesthesia
Dosage: GEL;OPHTHALMIC
| Strength | Dosage | Availability |
|---|---|---|
| 3% | GEL;OPHTHALMIC | Prescription |
12. Drug name - KATERZIA
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11471409 | AZURITY |
Oct, 2037
(14 years from now) | ||
| US11484498 | AZURITY |
Oct, 2037
(14 years from now) | ||
Drugs and Companies using AMLODIPINE BENZOATE ingredient
Market Authorisation Date: 08 July, 2019
Treatment: A method of treating coronary artery disease; A method of treating hypertension
Dosage: SUSPENSION;ORAL
| Strength | Dosage | Availability |
|---|---|---|
| EQ 1MG BASE/ML | SUSPENSION;ORAL | Prescription |
13. Drug name - KONVOMEP
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10751333 | AZURITY | Compositions and kits for omeprazole suspension |
Jul, 2039
(16 years from now) | |
| US11103492 | AZURITY | Compositions and kits for omeprazole suspension |
Jul, 2039
(16 years from now) | |
Drugs and Companies using OMEPRAZOLE; SODIUM BICARBONATE ingredient
Market Authorisation Date: 30 August, 2022
Treatment: NA
Dosage: FOR SUSPENSION;ORAL
| Strength | Dosage | Availability |
|---|---|---|
| 2MG/ML;84MG/ML | FOR SUSPENSION;ORAL | Prescription |
14. Drug name - KYPROLIS
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| USRE47954 | ONYX THERAP | Combination therapy with peptide epoxyketones |
Oct, 2029
(6 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Indication (I) | Aug 20, 2023 |
Drugs and Companies using CARFILZOMIB ingredient
Market Authorisation Date: 20 July, 2012
Treatment: Use in combination with lenalidomide plus dexamethasone for the treatment of patients with relapsed or refractory multiple myeloma who have received one to three lines of therapy
Dosage: POWDER;INTRAVENOUS
| Strength | Dosage | Availability |
|---|---|---|
| 10MG/VIAL | POWDER;INTRAVENOUS | Prescription |
| 30MG/VIAL | POWDER;INTRAVENOUS | Prescription |
| 60MG/VIAL | POWDER;INTRAVENOUS | Prescription |
15. Drug name - LYTGOBI
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US9108973 | TAIHO ONCOLOGY | 3,5-disubstituted alkynylbenzene compound and salt thereof |
Feb, 2033
(10 years from now) | |
| US10434103 | TAIHO ONCOLOGY | Crystal of 3,5-disubstituted benzene alkynyl compound |
Mar, 2036
(13 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | Sep 30, 2027 |
Drugs and Companies using FUTIBATINIB ingredient
Market Authorisation Date: 30 September, 2022
Treatment: NA
Dosage: TABLET;ORAL
| Strength | Dosage | Availability |
|---|---|---|
| 4MG | TABLET;ORAL | Prescription |
16. Drug name - MAKENA
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11446441 | COVIS | Prefilled syringe injector |
Jan, 2026
(3 years from now) | |
| US11446440 | COVIS | Needle assisted injection device having reduced trigger force |
Aug, 2031
(8 years from now) | |
Drugs and Companies using HYDROXYPROGESTERONE CAPROATE ingredient
Market Authorisation Date: 03 February, 2011
Treatment: NA
Dosage: SOLUTION;INTRAMUSCULAR; SOLUTION;SUBCUTANEOUS
| Strength | Dosage | Availability |
|---|---|---|
| 1250MG/5ML (250MG/ML) | SOLUTION;INTRAMUSCULAR | Prescription |
| 250MG/ML (250MG/ML) | SOLUTION;INTRAMUSCULAR | Prescription |
| 275MG/1.1ML (250MG/ML) | SOLUTION;SUBCUTANEOUS | Prescription |
17. Drug name - NOREPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11413259 | NEVAKAR INJECTABLES | Norepinephrine compositions and methods therefor |
Jan, 2038
(15 years from now) | |
| US10420735 | NEVAKAR INJECTABLES | Norepinephrine compositions and methods therefor |
Jan, 2038
(15 years from now) | |
| US10226436 | NEVAKAR INJECTABLES | Norepinephrine compositions and methods therefor |
Jan, 2038
(15 years from now) | |
| US10159657 | NEVAKAR INJECTABLES | Norepinephrine compositions and methods therefor |
Jan, 2038
(15 years from now) | |
| US10568850 | NEVAKAR INJECTABLES | Norepinephrine compositions and methods therefor |
Jan, 2038
(15 years from now) | |
Drugs and Companies using NOREPINEPHRINE BITARTRATE ingredient
Market Authorisation Date: 06 October, 2022
Treatment: Indicated to raise blood pressure in adult patients with severe, acute hypotension
Dosage: SOLUTION;INTRAVENOUS
| Strength | Dosage | Availability |
|---|---|---|
| EQ 4MG BASE/250 ML (EQ 16MCG BASE/ML) | SOLUTION;INTRAVENOUS | Prescription |
| EQ 8MG BASE/250ML (EQ 32MCG BASE/ML) | SOLUTION;INTRAVENOUS | Prescription |
| EQ 16MG BASE/250ML (EQ 64MCG BASE/ML) | SOLUTION;INTRAVENOUS | Prescription |
18. Drug name - OMLONTI
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US8648097 | SANTEN | Pyridylaminoacetic acid compound |
Oct, 2029
(6 years from now) | |
| US10774072 | SANTEN | Crystal of N-substituted sulfonamide compound |
Jun, 2035
(12 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8685986 | SANTEN | Medical composition for treatment or prophylaxis of glaucoma |
Oct, 2029
(6 years from now) | |
| US10179127 | SANTEN | Pharmaceutical formulations comprising a pyridylaminoacetic acid compound |
Jan, 2035
(12 years from now) | |
| US11197849 | SANTEN | Pharmaceutical formulations comprising a pyridylaminoacetic acid compound |
Jan, 2035
(12 years from now) | |
| US10702511 | SANTEN | Pharmaceutical formulations comprising a pyridylaminoacetic acid compound |
Jan, 2035
(12 years from now) | |
| US9415038 | SANTEN | Pharmaceutical formulations comprising a pyridylaminoacetic acid compound |
Jan, 2035
(12 years from now) | |
| USRE48183 | SANTEN | Pharmaceutical formulations comprising a pyridylaminoacetic acid compound |
Jan, 2035
(12 years from now) | |
| US10765750 | SANTEN | Pharmaceutical composition containing pyridylaminoacetic acid compound |
Jan, 2035
(12 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | Sep 22, 2027 |
Drugs and Companies using OMIDENEPAG ISOPROPYL ingredient
Market Authorisation Date: 22 September, 2022
Treatment: Method of treating open-angle glaucoma or ocular hypertension in patients
Dosage: SOLUTION;OPHTHALMIC
| Strength | Dosage | Availability |
|---|---|---|
| 0.002% | SOLUTION;OPHTHALMIC | Prescription |
19. Drug name - OTREXUP
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11446441 | OTTER PHARMS | Prefilled syringe injector |
Jan, 2026
(3 years from now) | |
Drugs and Companies using METHOTREXATE ingredient
Market Authorisation Date: 11 October, 2013
Treatment: NA
Dosage: SOLUTION;SUBCUTANEOUS
| Strength | Dosage | Availability |
|---|---|---|
| 7.5MG/0.4ML (7.5MG/0.4ML) | SOLUTION;SUBCUTANEOUS | Discontinued |
| 10MG/0.4ML (10MG/0.4ML) | SOLUTION;SUBCUTANEOUS | Discontinued |
| 12.5MG/0.4ML (12.5MG/0.4ML) | SOLUTION;SUBCUTANEOUS | Prescription |
| 15MG/0.4ML (15MG/0.4ML) | SOLUTION;SUBCUTANEOUS | Prescription |
| 17.5MG/0.4ML (17.5MG/0.4ML) | SOLUTION;SUBCUTANEOUS | Prescription |
| 20MG/0.4ML (20MG/0.4ML) | SOLUTION;SUBCUTANEOUS | Prescription |
| 22.5MG/0.4ML (22.5MG/0.4ML) | SOLUTION;SUBCUTANEOUS | Prescription |
| 25MG/0.4ML (25MG/0.4ML) | SOLUTION;SUBCUTANEOUS | Prescription |
| 15MG/0.6ML (15MG/0.6ML) | SOLUTION;SUBCUTANEOUS | Discontinued |
| 17.5MG/0.7ML (17.5MG/0.7ML) | SOLUTION;SUBCUTANEOUS | Discontinued |
| 20MG/0.8ML (20MG/0.8ML) | SOLUTION;SUBCUTANEOUS | Discontinued |
| 22.5MG/0.9ML (22.5MG/0.9ML) | SOLUTION;SUBCUTANEOUS | Discontinued |
| 25MG/ML (25MG/ML) | SOLUTION;SUBCUTANEOUS | Discontinued |
20. Drug name - OXBRYTA
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11452720 | GLOBAL BLOOD THERAPS | Crystalline polymorphs of the free base of 2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde |
Feb, 2035
(12 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | Nov 25, 2024 |
Drugs and Companies using VOXELOTOR ingredient
Market Authorisation Date: 17 December, 2021
Treatment: Treating sickle cell disease by administering voxelotor and another active agent
Dosage: TABLET, FOR SUSPENSION;ORAL
| Strength | Dosage | Availability |
|---|---|---|
| 300MG | TABLET, FOR SUSPENSION;ORAL | Prescription |
21. Drug name - OXLUMO
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US11446380 | ALNYLAM PHARMS INC | Compositions and methods for inhibition of HAO1 (hydroxyacid oxidase 1 (glycolate oxidase)) gene expression |
Oct, 2035
(12 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity (ODE) | Nov 23, 2027 |
| New Chemical Entity Exclusivity (NCE) | Nov 23, 2025 |
Drugs and Companies using LUMASIRAN SODIUM ingredient
Market Authorisation Date: 23 November, 2020
Treatment: NA
Dosage: SOLUTION;SUBCUTANEOUS
| Strength | Dosage | Availability |
|---|---|---|
| EQ 94.5MG/0.5ML BASE (EQ 94.5MG/0.5ML BASE) | SOLUTION;SUBCUTANEOUS | Prescription |
22. Drug name - PEDMARK
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10596190 | FENNEC PHARMS INC | Method for reducing ototoxicity in pediatric patients receiving platinum-based chemotherapy |
Jan, 2038
(15 years from now) | |
| US11291728 | FENNEC PHARMS INC | Anhydrous sodium thiosulfate and formulations thereof |
Jul, 2039
(16 years from now) | |
Drugs and Companies using SODIUM THIOSULFATE ingredient
Market Authorisation Date: 20 September, 2022
Treatment: A method of reducing ototoxicity in a human pediatric patient about 5 years of age or under with localized medulloblastoma comprising administering sodium thiosulfate about six hours after administration of cisplatin
Dosage: SOLUTION;INTRAVENOUS
| Strength | Dosage | Availability |
|---|---|---|
| 12.5GM/100ML (125MG/ML) | SOLUTION;INTRAVENOUS | Prescription |
23. Drug name - PEMAZYRE
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11466004 | INCYTE CORP | Solid forms of an FGFR inhibitor and processes for preparing the same |
May, 2039
(16 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | Apr 17, 2025 |
| Orphan Drug Exclusivity (ODE) | Apr 17, 2027 |
| New Indication (I) | Aug 26, 2025 |
Drugs and Companies using PEMIGATINIB ingredient
Market Authorisation Date: 17 April, 2020
Treatment: Treatment of previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fgfr2 fusion or other rearrangement by administering once daily a tablet containing about 0.5 mg to about 10 mg of pemigatinib; Treatment of previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fgfr2 fusion or other rearrangement by administering pemigatinib qd for 14 days then not administering pemigatinib for 7 days in a 21-day cycle; Treatment of previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fgfr2 fusion or other rearrangement by administering pemigatinib in a daily dose of about 5 mg to about 20 mg
Dosage: TABLET;ORAL
| Strength | Dosage | Availability |
|---|---|---|
| 4.5MG | TABLET;ORAL | Prescription |
| 9MG | TABLET;ORAL | Prescription |
| 13.5MG | TABLET;ORAL | Prescription |
24. Drug name - RECORLEV
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11478471 | STRONGBRIDGE |
Jan, 2026
(3 years from now) | ||
Drugs and Companies using LEVOKETOCONAZOLE ingredient
Market Authorisation Date: 30 December, 2021
Treatment: Treatment of endogenous hypercortisolemia in patients with cushing’s syndrome for whom surgery is not an option or has not been curative
Dosage: TABLET;ORAL
| Strength | Dosage | Availability |
|---|---|---|
| 150MG | TABLET;ORAL | Prescription |
25. Drug name - RELYVRIO
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10857162 | AMYLYX | Compositions for improving cell viability and methods of use thereof |
Dec, 2033
(11 years from now) | |
| US10251896 | AMYLYX | Compositions for improving cell viability and methods of use thereof |
Dec, 2033
(11 years from now) | |
| US9872865 | AMYLYX | Compositions for improving cell viability and methods of use thereof |
Dec, 2033
(11 years from now) | |
| US11071742 | AMYLYX | Compositions for improving cell viability and methods of use thereof |
Dec, 2033
(11 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | Sep 29, 2027 |
Drugs and Companies using SODIUM PHENYLBUTYRATE; TAURURSODIOL ingredient
Market Authorisation Date: 29 September, 2022
Treatment: Treatment of amyotrophic lateral sclerosis (als) in adults
Dosage: FOR SUSPENSION;ORAL
| Strength | Dosage | Availability |
|---|---|---|
| 3GM/PACKET; 1GM/PACKET | FOR SUSPENSION;ORAL | Prescription |
26. Drug name - SEGLENTIS
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11478488 | KOWA PHARMS |
Apr, 2030
(7 years from now) | ||
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Product (NP) | Oct 15, 2024 |
Drugs and Companies using CELECOXIB; TRAMADOL HYDROCHLORIDE ingredient
Market Authorisation Date: 15 October, 2021
Treatment: A method for treatment of pain in adults using tramadol hydrochloride and celecoxib
Dosage: TABLET;ORAL
| Strength | Dosage | Availability |
|---|---|---|
| 56MG;44MG | TABLET;ORAL | Prescription |
27. Drug name - SLYND
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11478487 | EXELTIS USA INC |
Jun, 2031
(8 years from now) | ||
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Product (NP) | May 23, 2022 |
Drugs and Companies using DROSPIRENONE ingredient
Market Authorisation Date: 23 May, 2019
Treatment: NA
Dosage: TABLET;ORAL
| Strength | Dosage | Availability |
|---|---|---|
| 4MG | TABLET;ORAL | Prescription |
28. Drug name - SPRAVATO
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11446260 | JANSSEN PHARMS | Pharmaceutical composition of S-ketamine hydrochloride |
Mar, 2034
(11 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | Mar 5, 2024 |
| New Indication (I) | Jul 31, 2023 |
Drugs and Companies using ESKETAMINE HYDROCHLORIDE ingredient
Market Authorisation Date: 05 March, 2019
Treatment: Treatment of depressive symptoms in adults with mdd with acute suicidal ideation or behavior by nasally administering 56mg or 84mg of esketamine as a pharmaceutical composition twice per week in conjunction with an oral antidepressant; Treatment of treatment-resistant depression in adults by nasally administering 56mg or 84mg of esketamine twice per week as a pharmaceutical composition in conjunction with an oral antidepressant; Treatment of treatment-resistant depression in adults by nasally administering 56mg or 84mg of esketamine as a pharmaceutical composition in conjunction with an oral antidepressant
Dosage: SPRAY;NASAL
| Strength | Dosage | Availability |
|---|---|---|
| EQ 28MG BASE | SPRAY;NASAL | Prescription |
29. Drug name - SUNOSI
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11439597 | AXSOME MALTA | Formulations of (R)-2-amino-3-phenylpropyl carbamate |
Nov, 2034
(11 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | Jun 17, 2024 |
| Orphan Drug Exclusivity (ODE) | Jun 17, 2026 |
Drugs and Companies using SOLRIAMFETOL HYDROCHLORIDE ingredient
Market Authorisation Date: 17 June, 2019
Treatment: NA
Dosage: TABLET;ORAL
| Strength | Dosage | Availability |
|---|---|---|
| EQ 75MG BASE | TABLET;ORAL | Prescription |
| EQ 150MG BASE | TABLET;ORAL | Prescription |
30. Drug name - TRIKAFTA (COPACKAGED)
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US11453655 | VERTEX PHARMS INC | Modulator of the cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator |
Dec, 2037
(15 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Patient Population (NPP) | Jun 8, 2024 |
| New Chemical Entity Exclusivity (NCE) | Oct 21, 2024 |
| Orphan Drug Exclusivity (ODE) | Dec 21, 2027 |
Drugs and Companies using ELEXACAFTOR, IVACAFTOR, TEZACAFTOR; IVACAFTOR ingredient
Market Authorisation Date: 21 October, 2019
Treatment: NA
Dosage: TABLET;ORAL
| Strength | Dosage | Availability |
|---|---|---|
| 50MG,37.5MG,25MG; 75MG | TABLET;ORAL | Prescription |
| 100MG,75MG,50MG; 150MG | TABLET;ORAL | Prescription |
31. Drug name - TRINTELLIX
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11458134 | TAKEDA PHARMS USA | 1-[2-(2,4-dimeihylphenylsulfanyl)-phenyl]piperazine as a compound with combined serotonin reuptake, 5-HT3 and 5-HT1A activity for the treatment of cognitive impairment |
Jun, 2027
(4 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| M | Jan 22, 2024 |
Drugs and Companies using VORTIOXETINE HYDROBROMIDE ingredient
Market Authorisation Date: 30 September, 2013
Treatment: Use of trintellix for the treatment of major depressive disorder (mdd) in adults
Dosage: TABLET;ORAL
| Strength | Dosage | Availability |
|---|---|---|
| EQ 5MG BASE | TABLET;ORAL | Prescription |
| EQ 10MG BASE | TABLET;ORAL | Prescription |
| EQ 15MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | TABLET;ORAL | Discontinued |
| EQ 20MG BASE | TABLET;ORAL | Prescription |
32. Drug name - YUPELRI
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11484531 | MYLAN IRELAND LTD |
Oct, 2039
(16 years from now) | ||
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | Nov 9, 2023 |
Drugs and Companies using REVEFENACIN ingredient
Market Authorisation Date: 09 November, 2018
Treatment: For the maintenance treatment of patients with chronic obstructive pulmonary disease (copd)
Dosage: SOLUTION;INHALATION
| Strength | Dosage | Availability |
|---|---|---|
| 175MCG/3ML | SOLUTION;INHALATION | Prescription |
33. Drug name - ZONISADE
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11478456 | AZURITY |
Aug, 2038
(15 years from now) | ||
Drugs and Companies using ZONISAMIDE ingredient
Market Authorisation Date: 15 July, 2022
Treatment: A method of treating seizures
Dosage: SUSPENSION;ORAL
| Strength | Dosage | Availability |
|---|---|---|
| 100MG/5ML | SUSPENSION;ORAL | Prescription |
availability in other generic markets.
Click on the highlighted region to filter.